"When I talk to executives from pharmaceutical companies they tell me that they want to do more for neglected diseases, but they at least need to get credit for it. The Access to Medicine Index does exactly that."

Bill Gates

Co-chair and Trustee, Bill & Melinda Gates Foundation

"The Access to Medicine Index is a very important project. What gets measured, gets done."

Dr. Margaret Chan

Former Director General, World Health Organisation

"This independent Antimicrobial Resistance Benchmark is a huge step forward and shines a light on the pharmaceutical industry’s progress in tackling drug-resistant infections. It can help pave the way for a transparent learning culture where best practice is shared, progress celebrated, and gaps where further work is needed are identified.”

Dame Sally Davies

Professor Dame Sally Davies, UK Special Envoy on Antimicrobial Resistance and Master of Trinity College, Cambridge

"You should be commended for taking on this difficult task in the environment of a consolidated industry with many atypical manufacturers playing important roles. We feel that the ATVI has struck a good balance, recognizing the elements that are important in access to vaccines, taking a systematic approach to comparing across manufacturers, yet recognizing and appreciating the differences in this industry."

Dr. Seth Berkley

CEO, the GAVI Alliance

“The pharmaceutical industry’s role in tackling drug-resistant infections extends beyond developing new treatments. The AMR Benchmark makes clear where companies are making commendable efforts to tackle this urgent global health problem – and it shows where further effort must now be focused. Wellcome is committed to working with industry and governments to answer the questions this report raises, by supporting new product development, and helping ensure antibiotics, old and new, are used appropriately and are available to all patients who need them.”

Jeremy Farrar

Director of the Wellcome Trust

“The AMR Benchmark is the first independent initiative that evaluates what pharmaceutical companies are doing to address AMR. It is clearly encouraging to see some actions to reduce the environmental pollution of antibiotics from manufacturing. However, there is still much room for improvement, particularly with regards to transparency. Incentives from outside, like the AMR Benchmark, are critically important to make sure that the pharmaceutical industry keeps moving forward.”

Joakim Larrson

Prof. Joakim Larsson, Director, Centre for Antibiotic Resistance Research (CARe) at University of Gothenburg, Sweden

"We desperately need new antibiotics, but we can’t let the new ones go to waste. The AMR Benchmark is an important tool to spur progress on innovation, appropriate use, and clean manufacturing, providing an independent assessment following the Davos Declaration and the Industry Roadmap released in 2016."

Kevin Outterson

Professor of Law at Boston University and Executive Director of CARB-X

"I’ve been impressed by the Access to Medicine Index. It presents well-balanced stakeholder views on good practices for the pharmaceutical industry and it provides clear standards against which the performance of individual companies can be judged."

Mary Robinson

President, Realizing Rights, Former UN High Commissioner for Human Rights (1997-2002), Former President of Ireland (1990-1997)

"The Access to Medicine Index mobilises the strength of the private sector, impacting the lives of millions of the most vulnerable people on earth. It showcases the synergy of aid, trade and investment."

Lilianne Ploumen

Former Minister for Foreign Trade and Development Cooperation

"There is more that we can do and are doing. This year, the index is tougher than ever. It challenges us to think harder about how we drive innovation and enable access to our products. This is a challenge that we are ready and willing to take on. We will continue to push ourselves to go further and faster to make sure our medicines and vaccines reach more people."

Sir Andrew Witty

Former CEO, GlaxoSmithKline plc

"Accountability is indispensable to the full implementation of the right to health, and the Access to Medicine Index plays an important role in promoting the responsibility of pharmaceutical corporations for a core element of the right to health – the right of everyone to access essential medicines."

Zeid Ra'ad Al Hussein

Former High Commissioner for Human Rights, United Nations

"But we at Novartis are only one piece of the puzzle. Tools like the Access to Medicine Index are useful in encouraging the pharmaceuticals industry to improve access."

Joseph Jimenez

Former CEO, Novartis AG

"This year’s index shows that the pharmaceutical industry has made progress in improving access to vital medicines for the globe’s poorest people, helping to tackle some of the world’s worst diseases. The deadly Ebola outbreak reminds us that there is still much to be done to stop the spread of diseases in developing countries."

The Rt Hon. Justine Greening

MP, Former Secretary of State for International Development,UK

"Licensing agreements between pharmaceutical companies and the Medicines Patent Pool can benefit 87-94% of people living with HIV in the developing world, and produce up to USD1.4 billion of savings for the international community. The Access to Medicine Foundation incentivises companies to engage with us and is one of our key partners to achieve impact."

Greg Perry

Assistant Director General, IFPMA

"The work of the Access to Medicine Foundation is powerful because it shows how pharmaceutical companies can and should integrate access to medicine into their business strategies. This empowers local civil society organisations to advocate for more sustainable initiatives."

Daniel Molokele

Executive Director AIDS Accountability, Pan African Civil Society Platform on Access to Medicines

"The Sustainable Development Goals and human rights demand accountability, which consists of monitoring, review and remedial action. By deepening monitoring, the Access to Medicine Foundation makes an indispensable contribution towards the accountability of pharmaceutical companies for the SDGs."

Paul Hunt

Professor of Law at Essex University, former UN Special Rapporteur on the right to health

"It is crucial for a CEO to have a dialogue with his/her company’s stakeholders. The Access to Medicine Index stimulates this dialogue, which is essential to bring all parties together. For this reason I highly recommend other sectors use this model as well."

Anthony Ruys

Chair Supervisory Board, STOP AIDS NOW, Former CEO of Heineken (1993-2006)

"The Access to Medicine Index has proven to provide much-needed transparency into pharmaceutical industry actions and policies. That will ultimately lead to greater access to healthcare for millions of people all over the globe."

Herman Wijffels

Former Executive Director, World Bank (2006-2008), Former Chair of Rabobank (1999-2006)

"Companies are beginning to understand that the value of corporate social responsibility programmes is not only the opportunity to do the right thing but that it's good for business as well. The Access to Medicine Index provides companies with a chance to improve performance and explore new business models while helping societies in need."

Knut Kjaer

Former CEO of RiskMetrics Group, Former CEO of Norges Bank Investment Management (NBIM)

"The AMR Benchmark brings much-needed clarity to how pharmaceutical companies approach AMR, which means investors can assess how pharmaceutical companies manage opportunities and risks created by drug-resistant infections. Such scrutiny by investors will spur pharma executives to greater activity."

Jim O'Neill

Former Chair of the UK Review on AMR

“The Sustainable Development Goals will only be achieved through close collaboration between the public and private sectors. Independent, data-driven benchmarks are essential to tracking and assessing progress against the world’s biggest challenges. This new Antimicrobial Resistance Benchmark will enable business, government, and civil society to work together to create a healthier, safer world against the emerging global threat posed by superbugs.”

Kathy Calvin

President and Chief Executive Officer of the United Nations Foundation.

“Without the cooperation and consensus of the biggest pharmaceutical companies and all of their stakeholders, it is impossible to address today’s global health challenges. There are still so many people worldwide who cannot access the medicine they need. At the same time, I see that the will from all stakeholders to reach them is rapidly growing.”

Wim Leereveld

Founder of the Access to Medicine Foundation.

“I welcome this comprehensive article on ending the burden of HIV, malaria and TB in children, and especially appreciate the strong emphasis on the crying need for children living with HIV to access the most up-to-date paediatric ARVs.”

Sister Mary Owens

Executive Director of COGRI - Nyumbani programs for children living with HIV

"I support the Access to Medicine Foundation's work to draw attention to the pressing issue of paediatric drug resistance and specifically pertaining to HIV, malaria and TB, along with their work to incentivise pharmaceutical companies to do more for children living in low-and-middle-income countries. Going forward, the need for new vaccines and treatments for children to address ongoing epidemics must not be forgotten.''

Professor Mike Sharland

Consultant in Paediatric Infectious Diseases at St George's University Hospitals NHS Foundation Trust

"No child should die of TB. That is why we’re working with our partners to expand the pediatric R&D pipeline. We welcome this new report for highlighting the progress to date and raising awareness of the work that still needs to be done to advance the development and delivery of new child-friendly MDR-TB treatments.”

Mel Spigelman

President and CEO, TB Alliance

"While COVID19 is dominating health systems globally, many children are still on the frontlines of the ‘big three’ infectious diseases — HIV, malaria and TB — all of which still require urgent vaccine development to save lives. The Access to Medicine Foundation provides important research and analysis on key paediatric access and drug resistance issues and incentivises companies to take action.''

Mette Gonggrijp

Former Ambassador for Women's Rights and Gender Equality, Dutch Ministry of Foreign Affairs

"COVID-19 has revealed that oxygen is an essential medicine in name only for the majority of patients who need it in low and middle-income countries. That’s why the Every Breath Counts Coalition is joining forces with the Access to Medicine Foundation to engage companies, corporate investors and global health agencies to work closely together to increase access to oxygen. These efforts will also reduce deaths from the many other conditions (e.g., neonatal, childhood pneumonia, childbirth, communicable and non-communicable diseases, and injuries) where oxygen can mean the difference between life and death."

Leith Greensdale

Coordinator, Every Breath Counts Coalition

“Nomura Asset Management was pleased to play a role in helping to identify key opportunities in the first-of-its-kind, multi-stakeholder effort convened by the Access to Medicine Foundation and Every Breath Counts Coalition for increasing access to medical oxygen in low- and middle- income countries. The Foundation’s model of company engagement proved successful in bringing major gas companies to the table to discuss tangible solutions for this critical issue now and in the future, particularly in light of COVID-19 and the achievement of Sustainable Development Goal 3.”

Alex Rowe

Nomura Asset Management

"The Access to Medicine Foundation’s research sheds light on issues that would otherwise remain underreported when it comes to the pharma industry and access to medicine and vaccines. This research informs priority setting and policy interventions based on the identified gaps."

John-Arne Røttingen

Ambassador for Global Health, Norwegian Ministry of Foreign Affairs

“The pharmaceutical industry’s role in tackling drug-resistant infections extends beyond developing new treatments. The AMR Benchmark makes clear where companies are making commendable efforts to tackle this urgent global health problem – and it shows where further effort must now be focused. Wellcome is committed to working with industry and governments to answer the questions this report raises, by supporting new product development, and helping ensure antibiotics, old and new, are used appropriately and are available to all patients who need them.”

Sir Jeremy Farrar

Director, the Wellcome Trust

“Full access to sexual and reproductive health and rights is the bedrock of gender equality. Pharmaceutical companies can help to pave the way forward, and the Access to Medicine Foundation plays a central role in encouraging them to fill treatment gaps and increase access to medicine for girls and women across the world.”

Katja Iversen

President & CEO, Women Deliver

"The Access to Medicine Index is an effective tool for incentivising companies to develop new vaccines to fight emerging infectious diseases, including coronavirus. When companies receive credit in the Access to Medicine Index, they are encouraged to work collaboratively with CEPI and the public sector and thereby contribute to advancing society's fight against these deadly diseases."

Richard Hatchett

CEO, Coalition for Epidemic Preparedness Innovations (CEPI)

"Responsible procurement can be a force for the public good to improve access to health technologies that are quality-assured and manufactured in an environmentally and socially responsible way. Yet, it requires credible data and rigorous research to work well. The Access to Medicine Foundation provides exactly this type of data and research, and this is why it is a long-lasting partner of United Nations Sustainable Procurement in the Health Sector (SPHS) agencies and global health financing institutions working together towards purchasing health commodities, including medicines, in a sustainable way."

Rosemary Kumwenda

Regional HIV/Health Team leader, SPHS Coordinator, UNDP

"This [Access to Vaccines] Index can help to identify product gaps as well as challenges on affordability, pricing policy transparency, research and development, and supply, to drive positive change and reach more people with life-saving vaccines.”

Seth Berkley

CEO, Gavi, the Vaccine Alliance

“Investing in the ACT-Accelerator is the best opportunity we have in the global fight against COVID-19. The Access to Medicine Foundation’s investor statement shows that institutional investors from all over the world recognise this and agree that cooperation on development, supply and distribution of COVID-19 tools is crucial – not only for people’s health – but also for mitigating the risk of exacerbating the ongoing global economic crisis. The global investment community has a unique position to engage with the pharmaceutical sector to fulfil their role in ramping up supply and making sure their products are available and affordable worldwide.”

Dag Inge Ulstein

Minister of International Development, Norway

“It is very positive to see that the investment community acknowledges the importance of expanding access to the full set of tools to fight the current pandemic, including treatments, diagnostics and medical oxygen. Given the challenges posed by the emergence of new virus variants, it has never been more important to ensure that these tools are available for everyone, everywhere. This is crucial to enhance disease control and hopefully decrease severe illness in the coming year.”

Dr Philippe Duneton

Executive Director, UNITAID

“The initiative coordinated by the Access to Medicine Foundation is a promising step from the investment community. CEPI’s approach relies on proactive partners from the pharmaceutical industry to fulfil its mission and create a world in which epidemics are no longer a threat to humanity. With this statement, more than 100 institutional investors from all over the world recognise the value of our work and commit to encourage their investee pharmaceutical companies to participate in R&D partnerships that accelerate the development and expand the availability of vaccines urgently needed to end COVID-19 and stop future epidemics. We must bring the pandemic under control as quickly as possible, so as to reduce the risk of further viral mutation, which could jeopardize all the gains of the last year.”

Dr Richard Hatchett

CEO, Coalition for Epidemic Preparedness Innovations (CEPI)

“We must urgently support low- and middle-income countries in reducing the impact from COVID-19 and mitigating the knock-on impact on other diseases, other health issues, education and poverty. Doing so is the right thing to do and the economic case for a bigger, faster response is compelling. Bringing forward the resumption of normal global economic activity by a week would pay for the US$ 27 billion requested by the ACT Accelerator several times over. Capital markets need to play a bigger role in the fight against COVID-19, and the investor statement coordinated by the Access to Medicine Foundation is a promising step to mobilize institutional investors with billions of assets under management as a force for the good. Global investors can support their investee companies to work with ACT Accelerator’s partners, accelerating research and development and, for example, reducing the risks associated with new strains. Investment managers can also develop finance mechanisms that mobilize funds which are desperately needed to deliver these new tools in all countries, as well as build security from future pandemics.”

Peter Sands

Executive Director, The Global Fund to Fight AIDS, Tuberculosis and Malaria

“COVID-19 has presented the world with one of the most significant socio-economic shocks in decades. Though the roll-out of vaccines is bringing us hope of a brighter future, there is still a long way to go and significant risks - both financial and physical - associated with new virus strains and uneven access to vaccines and other critical COVID-19 tools. Global institutional investors have a key role to play in protecting vulnerable populations and setting the stage for just and sustainable recovery. As the UN Office of the High Commissioner for Human Rights has made clear: ‘affordable, non-discriminatory access to the vaccine is a human right.’ This is why, today, I welcome the statement signed by more than 100 investors and coordinated by the Access to Medicine Foundation, calling for an effective, fair and equitable global response to COVID-19, including support for the Access to COVID-19 Tools (ACT) Accelerator.”

Fiona Reynolds

CEO, Principles for Responsible Investment

“Access to medicine has been a priority for our engagement with the pharmaceutical industry for several years. Signing the investor statement coordinated by the Access to Medicine Foundation therefore was the natural next step after engaging with more than 60 healthcare companies in 2020 alone. Collective action at the global level is essential to address this pandemic. The economic and financial damage triggered by COVID-19 knows no border. Symmetrically, a full and lasting recovery will need to be global. If we allow the pandemic to survive in any regions, every country, even those with the most advance healthcare systems and thorough vaccination programmes, will remain at risk.”

Marco Morelli

Executive Chairman, AXA Investment Managers

“A worrying lack of action across the pharmaceuticals and healthcare industry to ensure fair access to vaccines, treatments and diagnostics remains a major concern. COVID-19 treatment demands a global effort to prevent outbreaks and repeated re-emergence. EOS urges pharmaceutical companies to guarantee that a global access approach is implemented to assess country-specific needs and an equitable distribution.”

Katie Frame

Pharmaceuticals and Healthcare Engagement Lead, EOS at Federated Hermes

“Given how much we value the research and insights from the Access to Medicine Foundation on pharmaceutical company action in emerging markets, we are pleased to join this new initiative to contribute putting an end to the current pandemic. Long-term institutional investors have learnt the systemic risks for the global economy associated with infectious diseases and are committed to mitigate them as much as possible in the future. This will include bilateral and collaborative engagements with healthcare companies to ensure that they empower a strong public-private infrastructure of pandemic response and preparedness.”

Hiroyuki Horii

CIO and Executive Director, Sumitomo Mitsui Trust Asset Management

“The spread of new COVID-19 strains has made it even more urgent to launch rapid vaccination programmes covering as many people as possible, including in low- and middle-income countries. This is why we strongly support the initiative coordinated by the Access to Medicine Foundation and we look forward to continuing to work closely with the Foundation and our peer investors to promote an equitable global response to COVID-19 from governments and companies alike.”

Alex Rowe

Portfolio Manager and Equity Analyst, Nomura Asset Management

“The pandemic has had a devastating impact on societies and economies across the world. Ensuring widespread access to vaccines and associated healthcare technologies is one of the most pressing challenges of 2021. The crisis is a global one and its solutions will similarly have to span countries, both developed and emerging. It will require collaboration with industry, governments, and the international community.”

Andrew Howard

Global Head of Sustainable Investment, Schroders

“Ensuring developing economies have equal access to COVID-19 vaccines, medicines and tests will reduce the impact of COVID-19 worldwide and help foster a fairer and more sustainable global recovery. We’re keen to work with other global investors to explore ways we can encourage further investment that will help fund vaccine distribution.”

Debby Blakey


“As an investor in healthcare companies and social bonds, LGS has signed this statement endorsing its alignment with the Access to Medicine Foundation. Equitable funding promotes faster and more widespread eradication of disease which is vital in accelerating a global economic recovery that benefits our members and their future.”

Phil Stockwell

Chief Executive, Local Government Super

“The world celebrated the successful development of the COVID vaccines with elation; for the scientific and medical world this was a truly unparalleled breakthrough, and it came quickly enough that it was poised to change the course of the outbreak in a powerful way. Sadly, the uneven distribution across the world paints a much grimmer reality, where despite the technological advances a substantial portion of the world will wait for years. This will not only have an impact on millions of individuals, but also a steep economic cost which will be spread across the vaccine have and have-not countries alike. With the aim to support a return to normal for the global economy, GAM supports the Access to Medicine Foundation initiative to urge political leaders to think beyond their borders.”

Jenna Denyes

Senior Healthcare Analyst, GAM

“Equitable distribution of COVID vaccines and equipment is essential to overcoming the pandemic and emerging on solid economic and human rights footing. As shareholders representing our individual clients, we have a responsibility to use our collective voice and urge companies to take all stakeholders into consideration. This is a crucial time for investors to pool their strength to support access to COVID-19 vaccines and treatment equipment for all people.”

Maria Egan

Vice President and Director of Shareholder Engagement, Reynders, McVeigh Capital Management

“Inhabitants in the emerging world are already hard hit by the direct effects of climate change and health treatment in general lags behind the developed world. COVID-19 will affect income differences strongly. Vaccination programs should be available in the emerging markets on an equal basis. We all should contribute to the effective and sufficient distribution of vaccines around the world. Politicians, health care companies and investors can all play an important role here. There is no time to wait to act.”

Berry O. van Kollem

Partner, Providence Capital NV

“The COVID-19 pandemic has affected us all and put an enormous pressure on people, health systems, government and economies. As a global investor, the pandemic is increasing both ESG and financial risk of investments. The Access to Medicine Foundation’s investor statement shows that institutional investors from all over the world recognise this and agree that cooperation on development, supply and distribution of COVID-19 tools is crucial – not only for people’s health – but also for mitigating the risk of exacerbating the ongoing global economic crisis. The global investment community has a unique position to engage with the pharmaceutical sector to fulfil their role in ramping up supply and making sure their products are available and affordable worldwide.”

Jeanett Bergan

Head of Responsible Investments, KLP

“Desde La Mútua dels Enginyers creemos que es necesario dar una respuesta coordinada y a nivel global para luchar contra esta pandemia. Tenemos el objetivo de aportar nuestro granito de arena y mostrar nuestro apoyo a esta iniciativa de “Access to Medicine Foundation” para asegurar el acceso a las herramientas y vacunas contra el COVID-19 al mayor número de países posible. De este modo, esperamos contribuir para acelerar la recuperación económica mundial, mitigar los riesgos de mutación del virus y sentar las bases de actuación ante posibles futuras pandemias.”

Susanna Carmona

Managing Director, La Mútua dels Enginyers

“As Responsible and concerned investors, we are happy to stand behind this Global Investor Statement in support of an effective, fair and equitable response to COVID-19. The race to vaccinate the world’s population is rapidly becoming, in the words of UN Secretary Antonio Guterres, both “the biggest moral test before the global community” and a wildly uneven and unfair distribution”. Whilst rich countries and advanced economies squabble over supplies and surge ahead in COVID vaccinations – with only 10 countries having administered 75% of all COVID vaccinations to this point – 130 countries have not yet received a dose of vaccine. Experts are concerned that at this rate, mass vaccinations in the lowest income countries may not be realised till 2023 or 2024, wreaking havoc on already fragile health and economic systems and increasing poverty and social inequality, which for Ethical Partners, as Responsible Investors focussed on advocating for the attainment of the SDG’s 2 and 3 regarding health and poverty, is clearly a very concerning situation. Additionally, of concern to us as investors is the increasing understanding that this inequality of vaccine access will also be detrimental to global economic recovery efforts, with new modelling by the ICC showing that advanced economies stand to lose up to $9.2 trillion dollars through vaccine nationalism. The ICC study clearly shows “the economic costs of suboptimal vaccine distribution to the international trading system at the global scale, showing that even if a particular country has access to the vaccine, it “experiences a sluggish recovery with a drag on its GDP” if its trading partners do not have such access. Specifically it found that key advanced economies most impacted include many European countries (including Belgium, France, Germany, the Netherlands) Norway, Switzerland, the United Kingdom and the US, who might lose up to 3.9 percent of their GDPs relative to a world where all countries are vaccinated. Better health generally has been key to global growth over the past century, with economic historians estimating that improved health accounted for about one-third of the overall GDP-per-capita growth of developed economies in the past century. Furthermore, the continued circulation of COVID in unprotected populations further compromises the recovery of the world as a whole, increasing the risk of mutations and more dangerous variants –and further global economic and social impacts. We believe that this is why it is vital both morally and economically, that people in all countries receive protection from COVID-19, and that this widening gap is a topic of conversations for corporates, investors, governments and international organisations alike. We additionally agree that there is a clear and strong economic case for investing the Access to COVID-19 Tools (ACT) Accelerator, and echo the words of The WHO Director-General, Dr Tedros that the world faces both a catastrophic moral failure in equal access to the tools to combat the pandemic “but also a “potentially catastrophic economic failure”. As signatures to this important collaboration of investors, we therefore look forward to engaging with our portfolio companies wherever possible on addressing the equitable distribution of vaccinations globally, as well as participating in wider advocacy regarding the urgent and crucial need to act quickly to avoid this widening and deeply unequal gap in access to health – a prerequisite for both basic human rights, and to a functioning and thriving global economy.”

Robyn Parkin

Head of Sustainability, Ethical Partners Fund Management

“The longer Covid-19 is able to spread throughout populations, the more likely it is to develop new mutations that prolong the pandemic and harm the global economic recovery. Besides being the right thing to do, investing in the ACT-Accelerator is expected to prevent US$9.2 trillion in economic losses. The current budget shortfall of US$22.9 billion is miniscule compared to the economic benefits, making the business case for investing in the ACT-Accelerator crystal clear. VCIM supports this call to action and will continue to encourage pharmaceutical companies to promote access strategies and support the work of ACT-Accelerator.”

Kelly Hirsch

Senior ESG Analyst, Vancity Investment Management

“The COVID-19 crisis has served to highlight many forms of inequality across the world, and the need to build back a better, fairer and more sustainable economic system for all. This must begin with ensuring that the global response to the pandemic is available, effective and affordable for everyone. We commit to using our influence as capital allocators in supporting this response, and are pleased to join this initiative to encourage governments, companies and other investors to play their part in ensuring that nobody is left behind.”

Andrew Formica

CEO, Jupiter

“La pandemia ha dimostrato come il benessere sia un concetto multidimensionale, in cui salute delle persone e delle comunità economiche vanno di pari passo, in cui la globalizzazione produttiva degli anni ’90 dello scorso secolo ha lasciato il passo ad una globalizzazione che include tutti i fattori, a partire da quelli ambientali e sociali, come insegnano gli obiettivi dell’Agenda 2030. Per questo è fondamentale operare, anche nei processi di reazione, con uno sguardo globale sul mondo, garantendo a tutti le condizioni per ricominciare a guardare al future.”

Pierluigi Stefanini

Presidente, Gruppo Unipol

“Ensuring a swift and equitable response to COVID-19 – which includes supporting the fair distribution of vaccines and treatments around the world – is the strongest path to achieving a healthy global economic recovery. As long-term investors, we know that the actions taken now will impact whether we can fulfill our investment objectives in the future. It is therefore imperative that this recovery align with the development of a more sustainable global economy. The Access to Medicine Foundation’s statement serves as a valuable framework for investors as we look to engage healthcare companies on the vaccine’s distribution.”

Dave Zellner

Chief Investment Officer, Wespath

“I welcome this show of support for the ACT Accelerator from the investor community, which sends a strong message that vaccine equity is not only a moral but also an economic imperative. We will not end the pandemic anywhere until we end it everywhere. The longer the virus circulates, the longer trade and business will be disrupted and the longer the global recovery will take. Ending the pandemic, restoring confidence and rebooting the global economy requires all of us, in the public and private sectors, pulling in the same direction. I thank the Access to Medicine Foundation for adding its voice to the chorus demanding vaccine equity.”

Dr Tedros Adhanom Ghebreyesus

Director-General, World Health Organisation (WHO)

It is of paramount importance that these solutions become available to all, not just to residents of the wealthiest economies.

Willem Horstmann

Member of the Executive Board, Chief Risk Officer, Aegon Netherlands

“Having invested across both developed and emerging markets for more than three decades, Comgest considers itself very much a global citizen. We urge the global community to build deeper awareness of the myriad of interdependencies amongst countries, economies, citizens and natural resources. 2020 gave birth to a spirit of a global and shared destiny. Let’s make of 2021 the year of global solidarity.”

Sebastien Thevoux-Chabuel

Head of ESG, Comgest

“Global pandemics can only be tackled if we cooperate on a global scale. This is the reason why we support this initiative and actively engage with the pharmaceutical sector to provide worldwide access to vaccines and treatments.”

Rogier Krens

Chief Investment Officer, Achmea Investment Management

“The Access to Medicine Index shows that investor engagement works. We hope that more investors will join the initiative and contribute to us being able to both save lives and create conditions for fair growth.”

Carina Silberg

Head of Governance and Sustainability, Alecta

“Le informazioni provenienti dall’Access to Medicine Foundation sono un supporto essenziale per l’engagement di Etica Sgr sull’accesso ai farmaci, un tema su cui è importante chiamare all’azione le aziende ma anche i decisori politici e i regolatori.”

Aldo Bonati

Corporate Engagement and Networks Manager, Etica Sgr

“The Access to Medicines Index is a critical component of our research into pharmaceutical companies, providing insight into unmet global health needs and emerging markets trends, while helping us evaluate the relative role of large public issuers in advancing healthcare access in underserved communities.”

Carole Laible

CEO, Domini Impact Investments

“This pandemic has shown us how interconnected we all are. Equitable, global access to covid-19 vaccines and treatment is paramount for a sustained global recovery.”

Michela Gregory

Director of ESG Services, NEI Investments

“The COVID-19 pandemic has exposed the deep inequalities in society. By signing this statement, Alquity urges the global community to act in solidarity and ensure all people on the planet have equal access to vaccination and other Covid19 tools.”

Suresh Mistry

Co-Founder, Alquity Investment Management

“ACTIAM, an Access to Medicine signatory, has signed this statement as it is an advocate for a fair and equitable response to COVID-19 and for ensuring all countries are evenly supported. A response involving industry actions that promote an equitable strategy is aligned with our Sustainable investment policy and our view that social capital issues such as these have a financially material impact on our investments.”

Greta Fearman

Senior Responsible Investment Officer, ACTIAM

“As institutional investors, it is in our interest to have a fair and global response to COVID-19 to promote a recovery for both emerging and developed economies alike. The Access to COVID-19 Tools (ACT) Accelerator is the most comprehensive global answer to, and the most likely exit strategy from, the pandemic. Yet, even after the new commitments at the G7 meeting last week, it faces a US$ 22.9 billion billion funding gap. Together with other investors, Ethos therefore urges world leaders to finance the ACT Accelerator in full and is committed to engage with healthcare companies to ensure affordable prices of essential supplies for the ACT Accelerator's programmes.”

Vincent Kaufmann

CEO, Ethos Foundation and Ethos Services

“For years, we have been committed to a Fair Pharma with our engagement trajectory. Signing the investor statement coordinated by the Access to Medicine Foundation is an extension of this commitment and shows that we take up our role as an active shareholder to bring about positive change.”

Jonna Tjapkes

Senior Advisor Sustainability, ASN Bank

“An effective fair and equitable global response to Covid-19 is very obviously a worthy objective in its own right. But it is also very much in the interests of long-term investors as the prospects for sustained growth of the global economy are crucially dependent on the pandemic coming under control globally”.

Eoin Fahy

Head of Responsible Investing, KBI Global Investors

“The COVID-19 pandemic requires a coordinated and global response. A strong endorsement of this objective by the investment community is an important element for encouraging the necessary measures at the policy and industry level. Working with Access to Medicine Foundation and other investors allows us to exchange industry-specific expertise and enables us to collaboratively induce positive change.”

Matthias Born

Head of Investments & CIO Equities, Berenberg

“We believe that the opportunities emanating from biotechnological innovation to fight Covid-19 should not produce the contradictory result of hardening economic competition and sidelining less fortunate populations. At the end of the run, if the Covid-19 vaccines are not affordable and accessible, then they will not be sustainable. As an asset management firm with a unique tie to medical research, we are proud to join together with governments, scientists, businesses, civil society, and philanthropists and global health organizations to support the development and equitable distribution of Covid-19 solutions the world pressingly needs.”

Guillaume Mascotto

Vice President, Head of ESG and Investment Stewardship, American Century Investments

“As most of the worlds' populations holds its breath for more vaccines and better treatment, it is urgent that governments and pharmaceutical companies support The Access to COVID-19 Tools (ACT) Accelerator, a program whose objective is to ensure the coordinated, rapid and equitable development and distribution of tools aimed at combating the pandemic.”

Jean-Philippe Renaut

CEO, Æquo, Shareholder Engagement Services

“The impacts of the COVID-19 pandemic on a global scale demonstrate that one cannot envision a sustainable economy without global health. Funding for tools that aim to provide global and universal responses to this crisis, such as The Access to COVID-19 Tools (ACT) Accelerator, is crucial and urgent.”

Jo-Annie Pinto

Vice President, Communications and Responsible Investing, Hexavest

“As Dutch medical liability insurer we feel strongly about this issue because health doesn’t morally or economically abide by any physical or human drawn boundaries. The world should form a strong united front against COVID-19, that is the only viable way out for us all.”

Ebbo van Gelderen

CEO, MediRisk

“As the voice and support of healthcare professionals in the Netherlands we feel strongly about this issue, because access to good health is what every human being is entitled to. We, therefore, need to join forces in taking care of everyone's health to save the world from COVID-19.”

Bart Janknegt

CEO, VvAA Groep

“In the world from before, Western countries felt immune to pandemics, with diseases like SARS and Ebola mainly impacting Asian and African continents. And then COVID-19 appeared and spread across the globe in a matter of weeks, with new strains propagating rapidly despite global restrictions. While building the world that comes after, COVID19 response should be global and coordinated. Our planet should be considered as a whole, implying an access to vaccines for all human beings, independently from their physical location. As an asset manager with a strong focus on sustainable investing, we believe that the best approach to raise our voice is through collective engagement. We are pleased to be signatory of Access to Medicine Foundation’s Statement and fully support their actions.”

Nicolas Jamet

Portfolio Manager, RAM Active Investments

“Ensuring equitable access to COVID-19 vaccines and diagnostics across the world is paramount, in order to avoid significant lingering economic impacts from the pandemic. Market resiliency is clearly linked to our ability to protect global health, and we view the broad support for the Access to Medicine Foundation’s investor statement as a key indicator of this growing realization among the investor community.”

Jared Fernandez

ESG Analyst & Manager, Boston Trust Walden

“ICCR recognizes the strides that some pharmaceutical companies have taken to rapidly advance the development of therapeutics and vaccines for COVID-19. While we commend these efforts, we see that global access has been greatly restricted, which will enable the spread of virus variants and exacerbate the already dire economic crisis we are facing. The initiative coordinated by the Access to Medicine Foundation illustrates that the broader investment community agrees that decisions by healthcare companies will steer the trajectory of the global economy in the coming years, and that shareholders are willing to ensure that these decisions will be the right ones.”

Meg Jones-Monteiro

Program Director for Health Equity, ICCR

“Whether grappling with the implications of COVID or climate change, long term investors are acutely aware of the co-dependence of fair societies and thriving economies, both locally and globally. This statement highlights the crucial role that governments, companies and investors all have to play in delivering both.”

Stuart Palmer

Head of Ethics Research, Australian Ethical Investment

“At Castlefield, we believe that it is imperative that lower-income nations are not left behind in the race to roll out a vaccine and it is crucial that the acutely unequal power dynamics at play within vaccine manufacture and global health are recognised and addressed. We have therefore joined other investors calling for a clear strategy to ensure the fair and equitable distribution of COVID-19 vaccinations globally.”

Amelia Overd

Senior Executive, Investment Management, Co‑owner, Castlefield Investment Partners LLP

“As an investor dedicated to emerging and frontier markets for more than two decades, we are acutely aware of the environmental and social challenges facing societies in developing countries, among which poor access to healthcare, labour conditions and financial inclusion. While all countries are affected by the COVID-19 pandemic, many are ill-prepared to cope with it. We want to be part of the voice calling for an effective, fair and equitable approach to address this emergency. It is our strong belief that none of the UN Sustainable Development Goals, SDG3 included, will be reached globally, if solidarity and fairness are not part of the solutions.”

Karine Hirn

Partner, East Capital

“Access to COVID-19 Tools (ACT) is crucial to fight the pandemic, because the virus knows no borders and only a joint, global effort can really stop it. The European network for shareholder engagement "Shareholders for Change" has co-signed the investor statement coordinated by the Access to Medicine Foundation because equal access to an affordable health system is one of the core issues of our engagement with companies and countries. As share- and bondholders, we will be inspired by this initiative while engaging companies in the pharmaceutical sector in the coming AGM season and beyond.”

Aurélie Baudhuin

President of SfC

“The social and economic costs of COVID-19 are huge. One way to mitigate their further exponential growth is to ensure an effective, fair and equitable response, among others through aligned global vaccination capabilities and timelines. Van Lanschot Kempen welcomes the investor statement coordinated by the Access to Medicine Foundation. We as integrated wealth managers, with a commitment to long-term sustainable value creation find it critical to ensure communities around the world can recover from this pandemic equitably. Engaging with investee companies on ensuring access to vaccines and medication in lower income countries is part of our responsibility as active owners.”

Lars Dijkstra

Chief Investment Officer, Van Lanschot Kempen

“'We're in this together' cannot just be empty words. We need a robust equitable global response to the COVID-19 pandemic that meets urgent humanitarian needs and prevents catastrophic economic damage to low income country economies. It's past time to act."

Erik Mathiesen

Chief Financial Officer, The United Church of Canada

“It is well understood that the faster vaccination programs are rolled out around the world the greater the chance of preventing further variants of COVID-19 which have already challenged the efficacy of current vaccines. We also know that despite the efforts of the COVAX initiative, many of the poorest countries and most vulnerable people in the world will have very limited access to vaccines for a long period of time. Overcoming the pandemic requires equitable distribution of vaccines, particularly to the most vulnerable. Pharmaceutical companies are contributing in various ways including by waving IP, providing royalty free licences and offering vaccines at cost price. We applaud these efforts but they still fall far short of what is needed. As shareholders we recognise and support the importance of companies making short term sacrifices to fight the pandemic. We believe that aside from it being the right thing to do, it will benefit companies enormously in the long-term.”

Pablo Berrutti

Stewart Investors Sustainable Funds Group

“The GM Pensions Control Commission supports this initiative because the delay and lack of coordination in responding to the challenge that the pandemic poses to the world costs lives, deepens inequalities and delays economic recovery."

Mr Jorge Casilla

Representative of the board, GM Pensiones, Fondo de Pensiones

"The survival rate for childhood cancers is approximately 80% in high- income countries while, according to the WHO, less than 30% of children with cancer survive in low and middle-income countries (LMICs). Addressing this inequality is a social obligation. UICC welcomes this report and calls for all stakeholders to come together to improve access for new and existing medicines, and to simultaneously address other aspects of comprehensive treatment and care, like access to diagnostics, capacity building of the health work force and building a strong referral system."

Prof. Anil D’Cruz

President, The Union for International Cancer Control (UICC)

''ELMA greatly values the Access to Medicine Foundation and their work to make children and infants, and particularly those living in Sub-Saharan Africa, a bigger priority. Their new report outlines the issues impeding access, highlights potentially game-changing innovations for kids, and offers concrete solutions for a variety of stakeholders to consider for ramping up access. Together, we can ensure that investments in health innovations reach children urgently in need, including for neglected tropical diseases and HIV to move forward towards an AIDS-free generation.''

Tom McPartland

ELMA Philanthropies

“Affordable and easy access to healthcare is key for health and wellness and for sustainable growth in Emerging Market economies. We believe that this is equally crucial for the achievement of the UN’s Sustainable Development Goals, and that investors have a responsibility to act as an agent to drive impact. The Access to Medicine Index offers a clear and measurable way to improve healthcare in low- and middle- income countries by providing transparency and accountability for the actions of pharma companies, and to understand the difference that investors can make.”

Tassos Stassopoulos

Managing Partner and CIO, Trinetra Investment Management LLP

“Supporting and investing in the ACT-Accelerator is the best chance we have to save lives and livelihoods globally. Now more than ever we must recognize the importance of acting as one world, not many separate nations, for COVID-19 knows no such boundaries. As investors, we are keenly aware that a full global financial recovery from this pandemic won’t occur until the entire world has access to a safe and effective vaccine: Right now the ACT-Accelerator is our best hope for that future.”

Lydia Kuykendal

Director of Shareholder Advocacy, Mercy Investment Services, Inc.

“We will not end the pandemic anywhere until we end it everywhere. The more the virus circulates, the more opportunities it has to mutate in ways that could make vaccines less effective. And the longer the pandemic drags on, the longer trade and business will be disrupted and the longer the global recovery will take. Ending the pandemic, restoring confidence and rebooting the global economy requires all of us, in the public and private sectors, pulling in the same direction. I thank the Access to Medicine Foundation for adding its voice to the chorus demanding vaccine equity.”

Dr. Tedros Adhanom Ghebreyesus

Director-General, World Health Organisation

Back to top |